What Syngulon does

Syngulon is a Belgian synthetic biology startup developing original genetic technologies using bacteriocins — ribosomally-produced antimicrobial peptides — to improve microbial fermentation and address antimicrobial resistance. Founded in 2013 and headquartered in Charleroi, Belgium, the company operates a "Startup in the Labs" model with scientists embedded across academic partner laboratories in Belgium, Brazil, France, Germany, the Netherlands, and the United Kingdom. Its core technology platform is the PARAGEN collection, a proprietary library of natural and synthetic bacteriocin genetic elements; PARAGEN 1.0 enables rapid cell-free production and screening of 164 bacteriocins, of which 54% have demonstrated antimicrobial activity against tested indicator strains. The product portfolio is structured around three technology applications: antibiotic-free genetic selection (alternatives to antibiotic resistance markers for recombinant protein production), precision contamination control (protection of industrial bioprocesses from microbial contamination), and next-generation antimicrobials (targeted bacteriocin-based molecules against resistant pathogens).

Syngulon's go-to-market is B2B technology licensing. The company generates revenue by licensing its bacteriocin technologies and PARAGEN collection to industrial partners for integration into their own product development pipelines, with Elanco Animal Health (worldwide licensing agreement, March 2025) representing the first material disclosed commercial customer. Syngulon's customer base spans animal health companies (primary), industrial fermentation and bioeconomy firms (primary), pharmaceutical and healthcare players, and food and feed industry participants. All other disclosed partners — UCLouvain, ULiège, ULB, Imperial College London, UCL, UMons, Micalis INRAE, UNamur, DSM, Centrient Pharmaceuticals, and Tereos — participate in grant-funded R&D consortia (Horizon Europe, MSCA, ComRaDes, ELITHE, PROSECO, STOPPERSIST, STAPHCONTROL) rather than commercial revenue arrangements. The Scientific Advisory Board draws researchers from Belgium, France, and the USA, supporting the company's positioning in the European bioeconomy ecosystem through memberships in BIO, BioWin, Bioeconomy for Change, and Toulouse White Biotechnology.

The revenue model is licensing and royalties, supplemented by grant funding for R&D programs. Pricing is not publicly disclosed. With no disclosed funding rounds, no revenue figures, and a lean distributed operating model, the company is at an early commercial inflection point following the Elanco deal. Key risks include high customer concentration on a single licensee, dependence on continued grant funding for academic R&D programs, and the unproven commercial scalability of bacteriocin-based industrial applications at scale.

Name

Syngulon

Legal name

Syngulon SRL

Website

https://syngulon.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Syngulon is a Belgian synthetic biology startup that develops proprietary bacteriocin-based genetic technologies (the PARAGEN collection) to enable antibiotic-free selection, precision contamination control, and next-generation antimicrobials for industrial fermentation, animal health, and pharmaceutical partners via B2B licensing.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industries

Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD), Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG), Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Bacteriocin technology
• Microbial fermentation
• Antibiotic-free selection
• Synthetic biology
• Antimicrobial peptides

Headquarters

HQ city

Seraing

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Technology Licensing: Syngulon generates revenue through licensing its bacteriocin technologies and microbial selection systems to companies in animal health, industrial fermentation, and other bioeconomy sectors. The Elanco licensing agreement represents a major licensing partnership.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Syngulon develops and licenses proprietary bacteriocin-based genetic technologies organized around three application areas: antibiotic-free genetic selection for recombinant protein production, precision contamination control for industrial bioprocesses, and next-generation antimicrobials targeting resistant pathogens. The foundational offering is the PARAGEN collection, a proprietary library of natural and synthetic bacteriocin genetic elements organized by industrial application, deployed individually or as cocktails to shape microbial communities. Revenue is generated primarily by licensing these technologies and the PARAGEN library to industrial partners for integration into their fermentation and product development pipelines.

Product overview

Syngulon is a synthetic biology startup developing genetic technologies using bacteriocins. Their product portfolio consists of three core technology applications (Antibiotic-free Genetic Selection, Precision Contamination Control, and Next-generation Antimicrobials) built around their proprietary PARAGEN bacteriocin collection. The PARAGEN collection serves as the foundational DNA library enabling all three technology areas, with bacteriocins being deployed individually or in cocktails to shape microbial communities for industrial fermentation, animal health, and human health applications.

Differentiator

Problem solved

Functional benefit

Brands

• PARAGEN: Syngulon's collection of natural and synthetic bacteriocins organized by industrial application.

Products and services

• PARAGEN Collection A proprietary collection of natural and synthetic bacteriocin genetic elements organized by industrial application. Provided as a DNA library to industrial partners, the PARAGEN collection enables deployment of bacteriocins individually or in cocktails to shape microbial communities, control contamination, and replace antibiotic selection in microbial-based processes.
• Antibiotic-free Genetic Selection Sustainable bacteriocin-based alternatives to antibiotic resistance markers used in recombinant protein production and industrial biofermentation. Enables industrial partners to select and maintain production strains without relying on antibiotic selection, addressing antimicrobial resistance concerns and supporting cleaner biomanufacturing.
• Precision Contamination Control Advanced bacteriocin-based systems that actively protect industrial bioprocesses from microbial contamination. Designed for industrial fermentation operators seeking targeted, antibiotic-free contamination control to safeguard yields and product quality.
• Next-Generation Antimicrobials Novel bacteriocin-based molecules and cocktails designed through cell-free synthetic biology to offer targeted antimicrobial strategies against resistant pathogens. Targeted at pharmaceutical and healthcare applications where existing antibiotics are losing efficacy.

Quantifiable outcome

• 54% of synthesized bacteriocins showed antimicrobial activity against at least one indicator strain tested
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

16 partnerships are on record, tiered core, supporting and minor.

• Elanco Animal HealthcoreTechnology or Integration · 25 March 2026Worldwide licensing agreement for Syngulon's microbial selection technologies for animal health product development. Collaboration aims to enhance microbial stability and efficiency in fermentation processes supporting animal health innovations.
• UCLouvaincoreStrategic or Co-development Partner · 1 January 2023Multiple joint R&D programs including BREAKthrough (2023-2026), CRITIC (2022-2024), RPR (2017-2019), RPR 2 (2020-2022). UCLouvain hosts Syngulon scientists for bacteriocin research from Gram-positive bacteria.
• Micalis INRAEsupportingStrategic or Co-development Partner · 1 January 2021PROSECO research program (2021-2023) focused on proteases and serpins to control half-life of bacteriocins.
• UNamursupportingStrategic or Co-development Partner · 1 January 2021ELITHE consortium (2021-2025) developing the first biobased elicitor for wheat cultivation.
• Imperial College LondoncoreStrategic or Co-development Partner · 1 January 2019PhD doctoral training programs (BBSRC and MRC iCASE) from 2019-2022 focused on bacteriocin potential for human pathogen control including AMR and persistence. Dr. Ramesh Wigneshweraraj studies transcriptional regulatory basis of bacteriocin expression.
• ULiègecoreStrategic or Co-development Partner · 1 January 2018Long-standing R&D partner with programs including BaCLEM (2020-2023), ComRaDes (2018-2021), E.S.T. (2016-2019), and ELITHE (2021-2025). Prof. Frank Delvigne's lab supports scale-up of fermentation technologies.
• Université Libre de Bruxelles (ULB)coreStrategic or Co-development Partner · 1 January 2018Collaborative R&D through STOPPERSIST (2020-2024) and STAPHCONTROL (2019-2023) programs focused on bacteriocins against persistent bacteria and drug-resistant Staphylococcus aureus.
• University College LondoncoreStrategic or Co-development Partner · 1 January 2018EVOL-MODEL program (2018-2021) focused on evolutionary systems to increase bacteriocin properties and model microbial consortia. Dr. Chris Barnes provides modelling approaches for bacteriocin effects on industrial populations.
• DSMsupportingStrategic or Co-development Partner · 1 January 2018Industrial partner in ComRaDes program (2018-2021) developing scale-up/scale-down approaches to improve industrial fermentation.
• Centrient PharmaceuticalssupportingStrategic or Co-development Partner · 1 January 2018Industrial partner in ComRaDes program (2018-2021) for industrial fermentation improvement.
• Université de MonssupportingStrategic or Co-development Partner · 1 January 2017ALGOTECH program (2017-2020) focused on microalgae bioproduction optimization. Dr. Ruddy Wattiez's proteomics expertise supports understanding of biological impact of bacteriocin systems.
• TereossupportingStrategic or Co-development Partner · 1 January 2017PARAGEN program partner for development of bacteriocin library with industrial applications focus.
• BIO (Biotechnology Innovation Organization)minorOthersMember of BIO, the largest trade association representing biotechnology companies, academic institutions, and state biotechnology centers.
• BioWinminorOthersMember of BioWin, the Health and Biotech competitiveness cluster of Wallonia, Belgium.
• Bioeconomy for ChangeminorOthersMember of Bioeconomy for Change, a European bioeconomy industry association.
• Toulouse White BiotechnologyminorOthersMember of Toulouse White Biotechnology, a French biotechnology and bioeconomy industry cluster.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• DSM-Firmenich: Large nutrition, health, and industrial bioscience company with deep fermentation capabilities and an existing Syngulon R&D partner (DSM participated in the ComRaDes program). Competes for industrial fermentation customers and could either license Syngulon's technology or bundle in-house alternatives.
• Codexis: Established enzyme engineering company selling optimized proteins and biocatalysts into pharmaceutical and industrial fermentation markets. Competes for industrial biotechnology budgets and licensing-style revenue that Syngulon also targets via antibiotic-free selection.
• Amyris: Synthetic biology company engineering microbial strains for industrial fermentation of specialty ingredients. Comparable business model in industrial biotech and fermentation improvement, though at much larger scale and with vertically integrated product commercialization.
• Novonesis (Novozymes): Global leader in industrial enzymes and microbial solutions for fermentation, food, and animal health. Represents both a potential competitor and a logical strategic partner/licensee for Syngulon's bacteriocin contamination-control offerings.
• Ginkgo Bioworks: Large, publicly listed synthetic biology platform serving industrial fermentation customers with engineered strains and bioprocess optimization. Overlaps Syngulon's industrial fermentation and contamination-control use cases, with much broader toolkits and balance sheet.

Direct peers

• Eligo Bioscience: French biotech developing engineered bacteriocins ('elocins') for precision microbiome editing and antimicrobial applications. Closest direct analogue to Syngulon's PARAGEN-based bacteriocin platform, addressing AMR and microbiome modulation in similar therapeutic and industrial use cases.
• Locus Biosciences: Clinical-stage company engineering bacteriocin-like antimicrobials (engineered phage payloads producing bacteriocins) to target resistant pathogens. Comparable to Syngulon in combining synthetic biology with targeted antimicrobial design and competing for AMR-focused partnerships.

Emerging players

• Octant Bio: Synthetic biology platform company applying high-throughput chemistry and biology to engineer small-molecule and microbial therapeutics. Comparable in scale and stage to Syngulon and operates in overlapping synthetic biology toolkits for therapeutic and industrial applications.
• ContraFect: Clinical-stage developer of direct lytic agents (lysins) and other antimicrobial biologics for resistant infections. Adjacent emerging player in targeted antimicrobial biologics with overlapping AMR thesis, though focused on lysins rather than bacteriocins.
• SNIPR Biome: Clinical-stage biotech using CRISPR-based antimicrobials to selectively target pathogens in the microbiome. Comparable emerging competitor pursuing precision antimicrobial approaches against AMR-relevant bacteria, competing for similar partnership and licensing opportunities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/syngulon

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syngulon